Overview

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Status:
Not yet recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on vesatolimod (VES) pharmacokinetics (PK) and to evaluate safety in virologically suppressed adults with HIV-1 on antiretroviral therapy (ART).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Cobicistat
Rifabutin
Vesatolimod
Voriconazole